Skip to main content

Table 1 Summary of study design of the six trials

From: Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review

Study Marcellin Study 102 [14] Marcellin Study 103 [14] Lacombe [16] Hann [17] Peters [18] van Bommel [19]
Study location Worldwide Worldwide French multi-centre Asian-Americans Worldwide N/A
Study design randomized,double-blind randomized,double-blind non-randomized, open label quasi-randomized, open-label prospective randomized, double-blind Nonrandmoized,open-label
Grade 5 5 2 3 5 2
Treatment options Tenofovir 300 mg/d vs Adefovir 10 mg/d Tenofovir 300 mg/d vs Adefovir 10 mg/d Tenofovir 300 mg/d vs Adefovir 10 mg/d Tenofovir 300 mg/d vs Adefovir 10 mg/d Tenofovir 300 mg/d vs Adefovir 10 mg/d Tenofovir 300 mg/d vs Adefovir 10 mg/d
Male 193(77%) vs. 97(78%) 119(68%) vs. 64(71%) 54(96.4%) vs. 28(26.6%) 37(85%) vs. 49(76%) 24 (89%) vs. 24 (96%) 32(91.4%) vs. 14(77.8%)
Mean age, years 44 ± 10.6 vs. 43 ± 10 34 ± 11 vs. 34 ± 12 42.3 vs. 41.5 49 vs. 45 40 vs. 47 47 ± 2 vs. 45 ± 3.7
HBeAg-positive (%) 0:0 1:1 50(89.3%) vs. 25(86.2%) 33(75%) vs. 55(84%) 23 (85%) vs. 20 (80%) 31(89%) vs16( 89%)
Treatment (weeks) 48 weeks 48 weeks 48 weeks 48 weeks 48 weeks 72 to 130 weeks vs. 60 to 80 weeks
Follow-up (weeks) N/A N/A N/A 48 weeks 91 weeks vs. 81 weeks N/A
Status N/A N/A Coinfect HIV lamivudine-resistant Coinfect HIV lamivudine-resistant